GlaxoSmithKline (GSK)
GlaxoSmithKline Price: 44.28
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
GSK Price Rankings
| Overall | 83rd percentile | 1280 of 7685 |
| Sector | 89th percentile | 61 of 574 in Healthcare |
| Industry | 87th percentile | 4 of 31 in Drug Manufacturers - Major |
GSK Price Range, Past 5 Years
| Minimum | 27.27 | Mar 9 2009 |
| Maximum | 54.36 | Jan 9 2008 |
| Average | 41.70 |
About Price
The price of one share of stock, which is set by the market. Share price can be used to find a company's total market value, as represented by market capitalization.
Learn More
You may also be interested in these GSK related companies
GSK News
$GSK reacts to $HGSI poison pill. Stubborn, or what? It seems they do not want to get pushed or pulled.
about 3 days ago by OysterX
about 3 days ago by OysterX
GlaxoSmithKline Amends HGS Tender Offer to Address Poison Pill, Requires HGS to Redeem Pill
May 23, 8:37AM Benzinga
May 23, 8:37AM Benzinga
Canaccord Genuity maintains a 'Buy' on Auxilium Pharmaceuticals (AUXL); Bumping Guidance on Testim Partnership with GSK
May 22, 8:42AM Street Insider
May 22, 8:42AM Street Insider
Auxilium Pharma (AUXL), Glaxo (GSK) Enter Testim 1% Co-Promotion Agreement
May 21, 7:03AM Street Insider
May 21, 7:03AM Street Insider
Glaxo (GSK) Comments on Human Genome (HGSI) Bid Rejection; Will Continue with $13/Share Tender
May 17, 1:17PM Street Insider
May 17, 1:17PM Street Insider
Still think that $GSK will not succeed with $HGSI takeover at 13/share. They will increase the offer price, but probably not above 15.
about 9 days ago by OysterX
about 9 days ago by OysterX
News related to $GSK, currently 0.0% since open: 'Prestige Brands posts small fiscal 4Q loss' http://stks.co/3s9V
about 9 days ago by TradeBot
about 9 days ago by TradeBot
Human Genome Sciences (HGSI) Unanimously Rejects GlaxoSmithKline (GSK) Offer
May 17, 7:06AM Street Insider
May 17, 7:06AM Street Insider
$GSK Trametinib also in the spotlight at ASCO '12 with six presentations over 4 days. http://stks.co/3roL
about 9 days ago by abubnic
about 9 days ago by abubnic
$GSK Dabrafenib getting its share of attention at ASCO '12 with 50 presentations over 4 days. http://stks.co/3roI
about 9 days ago by abubnic
about 9 days ago by abubnic
$PFE $LLY $GSK So this is the condition some drug commercials warned us about! And we thought they were kidding. http://stks.co/3q2n
about 11 days ago by laughing_stock
about 11 days ago by laughing_stock
Don't see $XNPT popping 100% like $ARNA did, not as glamorous and still has to settle with $GSK. They would get 10 million if still partnrd
about 11 days ago by Glopolon
about 11 days ago by Glopolon
Barclays Maintains an 'Equalweight' on Human Genome Sciences (HGSI); Looking At $15/Share For GSK To Seal The Deal
May 14, 3:58PM Street Insider
May 14, 3:58PM Street Insider
$XNPT, No Debt, Drug has already been approved for RLS, so safety issues known. Court case with $GSK still out there, want settlement.
about 15 days ago by Glopolon
about 15 days ago by Glopolon
RT @JasonMilano8 $AMRN Here is a news about current CEO of Amarin selling his former company Reliant to ($GSK) in 2007: http://stks.co/3k0G
about 17 days ago by JasonMilano8
about 17 days ago by JasonMilano8
Breakfast Links | via @PointsnFigures http://stks.co/3jto $AMZN $GSK $HGSI $ZNGA
about 17 days ago by STNet
about 17 days ago by STNet
That's a surprise. $GSK goes hostile with $HGSI offer at 13. Did not expect that and am curious whether HGSI has something up its sleeve.
about 17 days ago by OysterX
about 17 days ago by OysterX
$AMRN Here is a news about current CEO of Amarin selling his former company Reliant to GlaxoSmithKline ($GSK) in 2007: http://stks.co/3jYt
about 17 days ago by JasonMilano8
about 17 days ago by JasonMilano8
$XNPT, Only non-dopaminergic option for RLS, is the advantage over generics. If $XNPT can work things out with $GSK, this should be $5+
about 18 days ago by Glopolon
about 18 days ago by Glopolon
Huf Post: Two Drugs Harness Immune System To Fight Cancer. http://stks.co/3iDa $DNDN $BMY $AZN $ONTY $GSK
about 18 days ago by abubnic
about 18 days ago by abubnic
$XNPT Sounds like Astellas is going to be better partner than $GSK, Hope they can work things out with $GSK re: Horizant.
about 20 days ago by Glopolon
about 20 days ago by Glopolon
$XNPT $GSK, FDA PDUFA date June 9th for Horizant treating postherpetic neuralgia. Horizant already approved in Japan for restless leg synd.
about 22 days ago by Glopolon
about 22 days ago by Glopolon
@WolfpackInvest I never hold long through PDUFA but I'm making an exception for $AMRN. Dont sell your position unles $PHE or $GSK are buying
about 25 days ago by junkmailman
about 25 days ago by junkmailman
$AMRN i still think GlaxoSmithKline ($GSK) will grab Amarin $AMRN around $20. We should see $AMRN here soon: http://stks.co/3aOF
about 26 days ago by JasonMilano8
about 26 days ago by JasonMilano8
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| GSK | 44.28 | +0.04 | +0.09% | 111.75B |
| GSIT | 4.20 | +0.00 | +0.00% | 120.25M |
| GSB | 2.15 | +0.03 | +1.42% | 39.15M |
| GSAT | 0.4049 | +0.03 | +6.58% | 120.61M |
| GS | 96.70 | -0.16 | -0.17% | 47.86B |
| GRZ | 3.29 | +0.07 | +2.17% | 195.89M |
| GRRF | 3.11 | +0.00 | +0.00% | 70.69M |
| GRO | 1.07 | +0.00 | +0.00% | 59.26M |
| GRMN | 43.19 | -0.53 | -1.21% | 8.406B |
| GRA | 52.56 | -1.03 | -1.92% | 3.886B |